Analysts expect DURECT Corporation (NASDAQ:DRRX) to report $-0.06 EPS on May, 9.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.06 EPS. After having $0.05 EPS previously, DURECT Corporation’s analysts see -220.00% EPS growth. The stock increased 1.45% or $0.03 during the last trading session, reaching $2.1. About 211,367 shares traded. DURECT Corporation (NASDAQ:DRRX) has risen 121.75% since April 24, 2017 and is uptrending. It has outperformed by 110.20% the S&P500.
Gazit-globe LTD. Ordinary Shares (NYSE:GZT) had a decrease of 11.11% in short interest. GZT’s SI was 3,200 shares in April as released by FINRA. Its down 11.11% from 3,600 shares previously. With 3,700 avg volume, 1 days are for Gazit-globe LTD. Ordinary Shares (NYSE:GZT)’s short sellers to cover GZT’s short positions. The stock decreased 1.67% or $0.1611 during the last trading session, reaching $9.4689. About 4,474 shares traded. Gazit Globe Ltd (NYSE:GZT) has declined 8.08% since April 24, 2017 and is downtrending. It has underperformed by 19.63% the S&P500.
Among 3 analysts covering Gazit Globe (NYSE:GZT), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Gazit Globe had 3 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Sell” rating given on Thursday, September 3 by TheStreet. The stock of Gazit Globe Ltd (NYSE:GZT) earned “Buy” rating by TD Securities on Friday, May 26. The firm has “Buy” rating by Chardan Capital Markets given on Thursday, September 3.
Gazit-Globe Ltd., through its subsidiaries, acquires, owns, develops, operates, and manages supermarket-anchored shopping centers in North America, Europe, and internationally. The company has market cap of $1.85 billion. As of December 31, 2016, the firm owned and operated 426 properties with a gross leasable area of approximately 6.6 million square meters in approximately 20 countries. It has a 13.39 P/E ratio.
Investors sentiment decreased to 2.04 in 2017 Q4. Its down 0.01, from 2.05 in 2017Q3. It is negative, as 9 investors sold DURECT Corporation shares while 16 reduced holdings. 17 funds opened positions while 34 raised stakes. 64.77 million shares or 0.77% less from 65.27 million shares in 2017Q3 were reported. Deutsche Bancshares Ag reported 0% in DURECT Corporation (NASDAQ:DRRX). Plante Moran Finance Ltd Liability Co holds 676 shares. Manufacturers Life The holds 0% or 127,315 shares in its portfolio. Wells Fargo & Commerce Mn reported 472,248 shares. Stratos Wealth Prtn Ltd reported 0% in DURECT Corporation (NASDAQ:DRRX). Vanguard Gp has 6.07M shares for 0% of their portfolio. Barclays Public Ltd accumulated 24,041 shares. Moreover, Alliancebernstein Ltd Partnership has 0% invested in DURECT Corporation (NASDAQ:DRRX). Jpmorgan Chase And Com invested in 0% or 30,951 shares. Legal General Gp Public Ltd Com invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Geode Mgmt Ltd Limited Liability Company holds 0% in DURECT Corporation (NASDAQ:DRRX) or 1.17M shares. Blume holds 0.01% or 31,000 shares. Ironwood Invest Mgmt Limited Liability stated it has 0.29% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Citadel Advsr Ltd invested in 0% or 98,397 shares. Prudential Fincl Inc, a New Jersey-based fund reported 13,940 shares.
Among 3 analysts covering Durect (NASDAQ:DRRX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Durect had 8 analyst reports since April 25, 2016 according to SRatingsIntel. The rating was upgraded by Stifel Nicolaus on Wednesday, July 12 to “Buy”. H.C. Wainwright downgraded DURECT Corporation (NASDAQ:DRRX) on Friday, October 20 to “Neutral” rating. The firm earned “Hold” rating on Friday, October 20 by Stifel Nicolaus. Rodman & Renshaw initiated the shares of DRRX in report on Monday, April 25 with “Buy” rating. On Friday, March 2 the stock rating was maintained by Stifel Nicolaus with “Hold”. H.C. Wainwright upgraded the stock to “Buy” rating in Tuesday, March 6 report. The firm has “Buy” rating given on Friday, June 23 by H.C. Wainwright. H.C. Wainwright initiated the stock with “Buy” rating in Monday, August 14 report.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company has market cap of $322.01 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. It currently has negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.